首頁CGEN • NASDAQ
add
Compugen Ltd
新聞內容
財務資料
損益表
收益
淨利
(USD) | 2023年12月info | 逐年變化幅度 |
---|---|---|
收益 | 3345.90萬 | 346.12% |
營業費用 | 1347.10萬 | 33.99% |
淨利 | 971.30萬 | 414.13% |
淨利潤率 | 29.03 | 170.41% |
每股盈餘 | 0.11 | 375.00% |
營業資金流動 | 1810.30萬 | 631.11% |
有效稅率 | 48.11% | — |
資產負債表
總資產
總負債
(USD) | 2023年12月info | 逐年變化幅度 |
---|---|---|
現金和短期投資 | 5068.50萬 | -39.19% |
總資產 | 1.21億 | 28.84% |
總負債 | 5577.50萬 | 238.11% |
總權益 | 6555.90萬 | — |
流通股份 | 8953.02萬 | — |
股價淨值比 | 2.86 | — |
資產報酬率 | 47.59% | — |
資本報酬率 | 73.98% | — |
現金流量
現金變動淨額
(USD) | 2023年12月info | 逐年變化幅度 |
---|---|---|
淨利 | 971.30萬 | 414.13% |
營運現金 | — | — |
投資現金 | — | — |
融資現金 | — | — |
現金變動淨額 | — | — |
自由現金流 | — | — |
簡介
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
執行長
成立時間
1993年2月10日
網站
員工數
68